COMP <GO>
TWST vs QGEN // RETURN ON INVESTED CAPITAL (ROIC)
Twist Bioscience Corporation (NASDAQ) VS. Qiagen N.V. (NYSE) • 15-METRIC TALLY: TWST 5
— QGEN 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: QGEN
LAST: $129.04 (-15.54%) • MKT CAP: $10.13B
roic
-11.70%
LAST: $50.35 (+0.26%) • MKT CAP: $10.35B
roic
8.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. QGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | QGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 62.20% | +32.00 | TWST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -11.70% | 8.00% | -19.70 | QGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 17.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 4.37% | -5.03 | QGEN | /fcf-yield <GO> |
| Operating Margin | -4.20% | 22.30% | -26.50 | QGEN | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 20.30% | -22.70 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 5.70% | +10.80 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.52% | -0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.54 | +22.46 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 71.0 | -22.60 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.95 | +0.03 | TWST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 22.7x | -1.70 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.13B | $10.35B | -$219.6M | QGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | QGEN REV | TWST GROSS % | QGEN GROSS % | TWST FCF | QGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $381.5M | $2.09B | — | 62.2% | -$75.6M | $453.3M |
| FY 2024 | $618.3M | $1.98B | — | 48.9% | -$69.2M | $506.4M |
| FY 2023 | $608.0M | $1.97B | — | — | -$142.5M | $371.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
QGEN // BETA 0.95